Onconetix (ONCO) Cash from Operations (2021 - 2026)
Onconetix (ONCO) posted quarterly Cash from Operations of 2100000.0 for Q1 2026, down 5.02% year-over-year from 2210917.36 in Q1 2025, and up 32.26% quarter-over-quarter from 3100000.0 in Q4 2025.
Onconetix (ONCO) Cash from Operations (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Cash from Operations for 6 consecutive years, with 2100000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 5.02% year-over-year to 2100000.0; the TTM figure through Mar 2026 stood at 9800320.0 (down 34.93% YoY), while the FY2025 annual figure was 9700000.0, up 7.58% from the prior year.
- Cash from Operations advanced to 2100000.0 in Q1 2026 per ONCO's latest filing, from 3100000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 9339929.0 in Q4 2023 and bottomed at 5232063.0 in Q1 2024.
- Historically, Cash from Operations has averaged 1817679.53 across 5 years, with a median of 2100000.0 in 2026.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 729.29% — and 2023, when it soared 433.56%.
- Onconetix's Cash from Operations stood at 2800042.0 in 2022, then jumped by 433.56% to 9339929.0 in 2023, then sank by 109.82% to 917647.0 in 2024, then tumbled by 237.82% to 3100000.0 in 2025, then surged by 32.26% to 2100000.0 in 2026.
- Business Quant data shows ONCO's Cash from Operations at 2100000.0 in Q1 2026, 3100000.0 in Q4 2025, and 3190024.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.92 Mn |
| Jun 30, 2026 | -1.92 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | -3.10 Mn |
| Dec 31, 2025 | -3.10 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Sep 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | -917,647.00 |
| Dec 31, 2024 | -917,647.00 |
| Sep 30, 2024 | -1.15 Mn |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -3.20 Mn |
| Jun 30, 2024 | -3.20 Mn |
| Mar 31, 2024 | -5.23 Mn |
| Mar 31, 2024 | -5.23 Mn |